Overview

• Linzagolix, branded as Yselty, has been fast-tracked by NICE for NHS use as a daily oral treatment for endometriosis.
• The medication works by blocking hormones that drive endometriosis symptoms and requires add-back hormone therapy to prevent side effects.
• Up to 1,000 women annually could benefit from this option, especially those unresponsive to previous medical or surgical treatments.
• Endometriosis affects 1.5 million women in the UK, with an average diagnosis delay of nine years, highlighting the need for improved care.
• NHS and government leaders describe the approval as a significant step in addressing a historically neglected area of women’s health.